Lantheus Holdings To Be Acquired By Curium For Up To $8 Bln
Lantheus (LNTH) said it agreed to be acquired by Curium, backed by CapVest, for up to $8 billion. Curium US will buy all LNTH shares for $102.50 cash plus non-transferable Contingent Value Rights up to $12 per share tied to milestones through 2030. Total up to $114.50 per share, a 38% premium. Deal expected to close in 1H 2027.
How this was made
The 30-second read
Why it matters
The definitive acquisition agreement sets a clear per-share cash price and adds milestone-based CVRs, creating immediate repricing and takeover-spread trading until closing in 1H 2027. Lantheus will remain independent until then and still reports Q2 2026 results on Aug 6, which can add incremental volatility.
Market read
A definitive, premium-priced acquisition announcement is a primary catalyst for LNTH, shifting focus to deal-spread, CVR valuation, and closing-risk monitoring into 1H 2027.
What to watch
Non-transferable CVRs tied to commercial milestones through 2030 can introduce uncertainty in ultimate value, and the financing mix (debt and equity) can affect deal economics and timing.
Background
Lantheus is a radiopharmaceutical company with a US commercial infrastructure and an F-18 prostate diagnostics franchise (including PYLARIFY). Curium is a radiopharmaceutical company backed by CapVest Partners.
Ticker impact
Lantheus agreed to be acquired by Curium for $102.50 per share in cash plus up to $12 CVRs tied to milestones through 2030.
Shares likely trade with deal-spread dynamics until definitive closing, with volatility around regulatory and integration headlines.
The article discloses the definitive agreement terms, per-share consideration, premium vs VWAPs, and expected closing window, which directly drives valuation and spread behavior.
Market effects
Signals consolidation in radiopharmaceuticals, potentially re-rating deal expectations and competitive positioning across radiodiagnostics and theranostics.
Primarily US-listed takeover dynamics, with potential cross-border manufacturing and commercialization integration effects.
Combines global manufacturing and therapy pipeline with US commercial infrastructure, affecting global radiopharma competitive landscape.
Counterpoint
The headline premium may not fully compensate for deal risk, including regulatory scrutiny and execution risk, so the spread can still move against the offer price.
Key entities
- public_companyLantheus Holdings, Inc.
Agreed to be acquired by Curium for $102.50 per share in cash plus up to $12 CVRs tied to commercial milestones through 2030.
- acquirerCurium
Radiopharmaceutical company acquiring all outstanding Lantheus shares; backed by CapVest Partners.
- private_investorCapVest Partners
Backs Curium, the acquirer in the announced transaction.
